Genomictree Inc.
228760
Rankning i aktier
#19158
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aktiekurs
$6.62
Marknadsvärde
$162.43M
Förändring (1 dag)
0.10%
Förändring (1 år)
-50.88%
Land
KR
Handel Genomictree Inc. (228760)
Kategori
Healthcare
EPS för Genomictree Inc. (228760)
EPS per 2026 TTM: 0
Enligt Genomictree Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Genomictree Inc. från 2026 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | ||
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
